Non-imidazole heterocyclic histamine H3 receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 10, 2003, Pages 1767-1770

  Chai, Wenying ^a   Breitenbucher, J Guy ^a   Kwok, Annette ^a   Li, Xiaobing ^a   Wong, Victoria ^a   Carruthers, Nicholas I ^a   Lovenberg, Timothy W ^a   Mazur, Curt ^a   Wilson, Sandy J ^a   Axe, Frank U ^a   Jones, Todd K ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HETEROCYCLIC COMPOUND; HISTAMINE H3 RECEPTOR ANTAGONIST; IMIDAZOPYRIDINE DERIVATIVE; INDOLE; INDOLIZINE DERIVATIVE; PYRAZOLOPYRIDINE; UNCLASSIFIED DRUG;

ARTICLE; DRUG SYNTHESIS; STRUCTURE ACTIVITY RELATION;

EID: 0038702085     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00299-3     Document Type: Article

References (21)

1. Dale H.H., Laidlaw P.P. J. Physiol. 41:1910;318.
2. Black J.W., Duncan W.A.M., Durant G.J., Ganellin C.R., Parsons M.E. Nature. 236:1972;385.
3. Arrang J.-M., Garbarg M., Schwartz J.-C. Nature. 302:1983;832.
4. Liu C., Ma X.-J., Jiang X., Wilson S.J., Hofstra C.L., Blevitt J., Pyati J., Li X., Chai W., Carruthers N., Lovenberg T.W. Mol. Pharmacol. 59:2001;420.
5. Arrang J.-M., Garbarg M., Schwartz J.-C. Neuroscience. 13:1987;149.
6. Arrang J.-M., Garbarg M., Schwartz J.-C. Neuroscience. 15:1985;553.
7. 3 Receptor; A Target for New Drugs, 1st ed.; Leurs, R., Timmerman, H., Eds.; Elsevier: Amsterdam, 1998; p 13.
8. 3 Receptor; A Target for New Drugs, 1st ed.; Leurs, R., Timmerman, H., Eds.; Elsevier: Amsterdam, 1998; p 59.
9. Arrang J.-M., Garbarg M., Lancelot J.-C., Lecomte J.-M., Pollard H., Robba M., Schunack W., Schwartz J.-C. Nature. 327:1987;117.
10. 3 Receptor; A Target for New Drugs, 1st ed.; Leurs, R., Timmerman, H., Eds.; Elsevier: Amsterdam, 1998; p 177.
11. Shah C., McAtee L., Breitenbucher J.G., Rudolph D., Li X., Lovenberg T.W., Mazur C., Wilson S.J., Carruthers N.I. Bioorg. Med. Chem. Lett. 12:2002;3309.
12. Lovenberg T.W., Roland B.L., Wilson S.J., Jiang X., Pyati J., Huvar A., Jackson M.R., Erlander M.G. Mol. Pharmacol. 55:1999;1101.
13. Meier G., Apelt J., Reichert U., Grabmann S., Ligneau X., Elz S., Leurquin F., Ganellin C.R., Schwartz J.-C., Schunack W., Stark H. Eur. J. Pharm. Sci. 13:2001;249.
14. Ganellin C.R., Leurquin F., Piripitsi A., Arrang J.-M., Garbarg M., Ligneau X., Schunack W., Schwartz J.-C. Arch. Pharm. Med. Chem. 331:1998;395.
15. Cheng Y.-C., Prusoff W.H. Biochem. Pharmacol. 22:1973;3099.
16. 2=0.827. The sites of protonation for the heterocycles were N-1, C-3, C-3, and N-1 for compounds 2, 3, 18, and 20, respectively. The proton affinities were calculated at the B3LYP/cc-pVTZ(-f)++//B3LYP/6-31G** level of theory using Jaguar 4.1, Schrodinger Inc, Portland, OR, 1991-2000.
17. Gilbert J.C., Weerasooriya U. J. Org. Chem. 47:1982;1837.
18. Seyferth D., Marmor R.S., Hilbert P. J. Org. Chem. 36:1971;1379.
19. Zhang H.-C., Ye H., Moretto A.F., Brumfield K.K., Maryanoff B.E. Org. Lett. 2:2000;89.
20. Coleman R.S., Grant E.B. Tetrahedron Lett. 35:1994;8341.
21. Okamoto, T.; Hirobe, M.; Suzue, S.; Nagatsu, Y.; Ushiyama, K.; Satoh, S.; Irikura, T. Ger. Offen. 2118917, 1972; Chem. Abstr. 1972, 77, 419671.